Phase 3-proven IV nimodipine chasing approval after a manufacturing-only CRL, with $17M and a Q2 2027 runway to close the CMC gap

Updated 49d ago

Grace Therapeutics is a late-stage biotech company developing an intravenous drug to prevent blood pressure drops after brain aneurysm rupture, which is not yet approved.

GTx-104, an intravenous formulation of nimodipine designed to prevent dangerous drops in blood pressure after brain aneurysm rupture, met its Phase 3 primary endpoint and received a CRL citing only manufacturing deficiencies. FDA confirmed no clinical or efficacy deficiencies in July 2026 Type A meeting minutes, leaving approvability contingent solely on resolving cGMP and leachables items. The critical risk is whether the dual-source manufacturing remediation completes before the $17M cash runway expires in Q2 2027.

Status

Challenged

Conviction

Current Thesis Drivers

STRIVE-ON met primary endpoint; FDA confirmed no clinical deficiencies
Approvability unresolved — resubmission timing tied to open CMC remediation
Cash $17M; runway Q2 2027 with no approved revenue
CRL issued April 2026 on CMC/manufacturing grounds only

What could change the thesis?

NDA resubmission accepted and approved: thesis restored; rejected or delayed past Q2 2027: financing crisis
Warrant exercises ($15M available): funds runway extension; exercises fail: accelerates dilutive raise
GTx-102 Phase 3 initiation vs. Quince: first-mover shapes endpoints; delay cedes orphan advantage

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

3 programs · 9 catalysts

Stress Test